TRANSTHERA-B (02617) opened higher by more than 8%. As of the time of writing, the stock is up 8.12% to HK$43.92, with a turnover of HK$2.1082 million. On the news front, on May 26, TRANSTHERA-B announced that its core product, Tinengotinib (TT00420), in combination with novel hormonal therapy (NHT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed after prior therapy, has received approval for a Phase II clinical trial from the National Medical Products Administration (NMPA) on May 25, 2026. Tinengotinib monotherapy has already demonstrated encouraging anti-tumor efficacy in mCRPC patients who have undergone multiple prior lines of treatment. Furthermore, Tinengotinib monotherapy for mCRPC received Fast Track Designation (FTD) from the U.S. FDA in June 2025. Tinengotinib is the world's first and only investigational drug that simultaneously inhibits the FGFR and JAK pathways and has clinical efficacy evidence in mCRPC. Currently, NHT has become the standard treatment for mCRPC patients, but resistance often develops after a period of NHT therapy. Recent research has found that activation of the FGFR and JAK pathways can promote the transformation of androgen-sensitive cancer cells into neuroendocrine cancer cells, leading to drug resistance. Simultaneous inhibition of the FGFR and JAK pathways can reverse this cellular state transition or lineage reprogramming, restoring cancer cell sensitivity to androgens and re-sensitizing them to NHT treatment.